Presenting Pivotal Phase 3 Sickle Cell Data at EHA 2026- Agios Pharmaceuticals
Agios Pharmaceuticals shared a post on LinkedIn:
“Agios News: Today, during the Plenary Abstracts Session at EHA 2026, we presented detailed results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.
This oral presentation included new transfusion burden and hemoglobin responder analyses that reinforce the strong anti-hemolytic profile of our first-in-class PK activator.
Read the results.”
Mohamed A., Franchise Director, Blood Disorders, Rare Disease GCC at NewBridge Pharmaceuticals, shared this post on LinkedIn:
“Results from the Rise up Phase 3 trial – the first pivotal trial to validate pyruvate kinase (PK) activation as a new treatment approach in Sickle Cell Disease.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Jun 16, 2026, 16:17Megan Lynch: Thrilled to Join AstraZeneca
-
Jun 16, 2026, 16:00Denise M: Two Partners, One Mission – Securing the Future of Blood
-
Jun 16, 2026, 15:4910 Posts Not To Miss From EHA 2026
-
Jun 16, 2026, 15:48Yan Leyfman: Can a Blood Test Reveal which Cells in Your Body are Aging Fastest?
-
Jun 16, 2026, 15:24Hiteshi K.C. Chauhan: Oral Anticoagulant Reversal in Major Bleeding and Urgent Surgery
-
Jun 16, 2026, 14:50Abdulrahman Nasiri: Honored to Share our Research Contributions at the EHA 2026
-
Jun 16, 2026, 14:49An Overview of Bernard–Soulier Syndrome – ICHCC
-
Jun 16, 2026, 14:47David Walcott: Blood Supply as Essential Healthcare Infrastructure
-
Jun 16, 2026, 14:36Catalin Bobirca: EHA 2026 Showcases the Future of Hemoglobinopathies Care